Almirall, S.A.

MCE:ALM.MC

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💄 Cosmetics

💊 Drugstores & Retail Pharmacies

Location

Spain

Market Cap

USD 2.64 B

Share Price

USD 12.30

Avg Daily Volume

140,564

Change (1 day)

-1.60%

Change (1 year)

16.85%

Change (YTD)

44.21%

Almirall, S.A. Total Liabilities for the year ending December 31, 2024: USD 940.52 M

Almirall, S.A. Total Liabilities is USD 940.52 M for the year ending December 31, 2024, a -6.52% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Almirall, S.A. Total Liabilities for the year ending December 31, 2023 was USD 1.01 B, a 13.44% change year over year.
Almirall, S.A. Total Liabilities for the year ending December 31, 2022 was USD 886.95 M, a -8.95% change year over year.
Almirall, S.A. Total Liabilities for the year ending December 31, 2021 was USD 974.09 M, a -19.30% change year over year.
Almirall, S.A. Total Liabilities for the year ending December 31, 2020 was USD 1.21 B, a -7.24% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

MCE: ALM.MC

Almirall, S.A.

CEO	Mr. Carlos Gallardo Piqué
IPO Date	June 20, 2007
Location	Spain
Headquarters	Ronda Del General Miter, 151
Employees	2,026
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💄 Cosmetics 💊 Drugstores & Retail Pharmacies

Description

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.